Abemaciclib
Information
- Drug Name
- Abemaciclib
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung non-small cell carcinoma | KRAS MUTATION KRAS MUTATION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 27217383 | Detail |
| lung non-small cell carcinoma |
KRAS p.Ala146Val (p.A146V) ( ENST00000311936.8, ENST00000557334.6, ENST00000256078.10, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Ala146Val (p.A146V) ( ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) |
C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 24836576 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In this multicenter phase I study of abemaciclib, ... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Case report of a patient with metastatic lung aden... | KRAS |
KRAS p.Ala146Val (p.A146V) ( ENST00000311936.8, ENST00000557334.6, ENST00000256078.10, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Ala146Val (p.A146V) ( ENST00000256078.10, ENST00000311936.8, ENST00000557334.6, ENST00000685328.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02107703 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer | July 22, 2014 | December 30, 2024 |
| NCT02747004 | Active, not recruiting | Phase 2 | A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer | September 14, 2016 | December 30, 2024 |
| NCT04238819 | Active, not recruiting | Phase 1/Phase 2 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | November 9, 2020 | October 2028 |
| NCT04616183 | Active, not recruiting | Phase 1/Phase 2 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | December 2, 2020 | December 31, 2025 |
| NCT03531645 | Active, not recruiting | Phase 2 | Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma | August 13, 2019 | September 30, 2024 |
| NCT03643510 | Active, not recruiting | Phase 2 | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | August 21, 2018 | August 2026 |
| NCT03654833 | Active, not recruiting | Phase 2 | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma | January 28, 2019 | October 31, 2023 |
| NCT04227327 | Active, not recruiting | Phase 2 | Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) | January 7, 2020 | December 2023 |
| NCT02152631 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer | October 3, 2014 | December 31, 2024 |
| NCT04627064 | Active, not recruiting | Phase 1 | ABEMA Alone or in COMBO With MK-6482 | December 31, 2020 | December 31, 2025 |
| NCT03706365 | Active, not recruiting | Phase 2/Phase 3 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | November 26, 2018 | June 2026 |
| NCT04481113 | Active, not recruiting | Phase 1 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | June 7, 2021 | December 30, 2025 |
| NCT04603183 | Active, not recruiting | Phase 2 | ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | June 2, 2021 | June 30, 2025 |
| NCT04188548 | Active, not recruiting | Phase 1 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | December 10, 2019 | December 2027 |
| NCT02246621 | Active, not recruiting | Phase 3 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer | November 6, 2014 | December 16, 2024 |
| NCT05169567 | Active, not recruiting | Phase 3 | Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer | March 11, 2022 | February 16, 2026 |
| NCT05999968 | Active, not recruiting | Phase 1 | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | January 12, 2024 | July 2026 |
| NCT02763566 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer | December 5, 2016 | December 31, 2024 |
| NCT03905889 | Active, not recruiting | Phase 1 | A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | June 5, 2019 | November 5, 2024 |
| NCT03939897 | Active, not recruiting | Phase 1/Phase 2 | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | June 17, 2020 | March 11, 2025 |
| NCT02779751 | Active, not recruiting | Phase 1 | A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | November 14, 2016 | December 31, 2024 |
| NCT05288166 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | April 14, 2022 | October 2027 |
| NCT04931342 | Active, not recruiting | Phase 2 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | October 7, 2021 | December 31, 2028 |
| NCT02791334 | Active, not recruiting | Phase 1 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | June 29, 2016 | July 2024 |
| NCT05759949 | Active, not recruiting | Phase 1 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | March 29, 2023 | July 25, 2024 |
| NCT04393285 | Active, not recruiting | Phase 2 | Abemaciclib and Letrozole to Treat Endometrial Cancer | October 10, 2020 | December 1, 2025 |
| NCT05617885 | Active, not recruiting | Phase 1/Phase 2 | Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | August 9, 2023 | June 1, 2026 |
| NCT02846987 | Active, not recruiting | Phase 2 | Study of Abemaciclib in Dedifferentiated Liposarcoma | July 2016 | July 2024 |
| NCT04074785 | Active, not recruiting | Early Phase 1 | Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 | December 13, 2019 | October 24, 2025 |
| NCT04752332 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer | May 10, 2021 | June 30, 2024 |
| NCT04751929 | Active, not recruiting | Phase 2 | Abemaciclib With or Without Atezolizumab for mCRPC | August 20, 2021 | December 20, 2025 |
| NCT04545710 | Active, not recruiting | Phase 2 | Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance | November 21, 2020 | December 1, 2023 |
| NCT04552769 | Active, not recruiting | Phase 2 | Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | September 10, 2020 | December 2024 |
| NCT04352777 | Active, not recruiting | Phase 2 | Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer | September 14, 2020 | December 30, 2024 |
| NCT02981940 | Active, not recruiting | Phase 2 | A Study of Abemaciclib in Recurrent Glioblastoma | February 9, 2017 | June 2025 |
| NCT03099174 | Active, not recruiting | Phase 1 | This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. | May 4, 2017 | May 30, 2024 |
| NCT04293393 | Active, not recruiting | Phase 2 | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients | October 2, 2020 | February 28, 2033 |
| NCT03155997 | Active, not recruiting | Phase 3 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | July 12, 2017 | May 28, 2029 |
| NCT03220646 | Active, not recruiting | Phase 2 | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | July 13, 2017 | July 2024 |
| NCT03280563 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | December 26, 2017 | December 31, 2024 |
| NCT03284957 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | September 20, 2017 | December 29, 2027 |
| NCT02792725 | Approved for marketing | Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | |||
| NCT03763604 | Available | Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | |||
| NCT02450539 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer | August 6, 2015 | July 29, 2020 |
| NCT02644460 | Completed | Phase 1 | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | February 2016 | October 10, 2023 |
| NCT02675231 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer | May 23, 2016 | November 9, 2023 |
| NCT04408924 | Completed | Phase 2 | Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer | January 20, 2021 | June 2, 2023 |
| NCT02677844 | Completed | Phase 1 | A Study of Abemaciclib in Healthy Participants | February 2016 | July 2016 |
| NCT02688088 | Completed | Phase 1 | A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body | March 8, 2016 | January 6, 2021 |
| NCT04514159 | Completed | Phase 1 | A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | November 12, 2020 | October 24, 2022 |
| NCT02079636 | Completed | Phase 1 | A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | March 28, 2014 | August 29, 2019 |
| NCT02745769 | Completed | Phase 1 | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | October 21, 2016 | January 22, 2019 |
| NCT04707196 | Completed | Phase 4 | A Study of Abemaciclib in Indian Women With Advanced Breast Cancer | February 22, 2021 | January 9, 2023 |
| NCT02784795 | Completed | Phase 1 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | November 4, 2016 | February 13, 2020 |
| NCT02831530 | Completed | Phase 2 | Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients | March 16, 2016 | February 2, 2018 |
| NCT02857270 | Completed | Phase 1 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | September 29, 2016 | October 24, 2022 |
| NCT02884089 | Completed | Phase 1 | A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants | August 2016 | December 2016 |
| NCT02919696 | Completed | Phase 1 | A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers | August 7, 2017 | September 3, 2019 |
| NCT02102490 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread | June 10, 2014 | October 22, 2018 |
| NCT02981342 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | January 12, 2017 | November 9, 2018 |
| NCT03292250 | Completed | Phase 2 | Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] | September 10, 2017 | March 10, 2022 |
| NCT03339843 | Completed | Phase 2 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib | December 19, 2018 | December 20, 2023 |
| NCT03356223 | Completed | Phase 2 | Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 | February 5, 2018 | December 5, 2022 |
| NCT02117648 | Completed | Phase 1 | A Study of LY2835219 in Participants With Cancer | April 2014 | August 2015 |
| NCT03703466 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer | November 28, 2018 | March 9, 2023 |
| NCT02308020 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | April 20, 2015 | November 8, 2019 |
| NCT02387814 | Completed | Phase 1 | A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment | March 2015 | August 2015 |
| NCT02411591 | Completed | Phase 1 | A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) | June 4, 2015 | May 28, 2019 |
| NCT05789771 | Completed | Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. | April 1, 2022 | December 1, 2022 | |
| NCT01655225 | Completed | Phase 1 | A Study of LY3023414 in Participants With Advanced Cancer | July 31, 2012 | February 2, 2022 |
| NCT02441946 | Completed | Phase 2 | A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer | August 2015 | February 12, 2018 |
| NCT04071262 | Completed | Phase 1 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer | December 20, 2019 | August 30, 2021 |
| NCT05141240 | Completed | A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors | April 15, 2020 | June 15, 2020 | |
| NCT02482935 | Completed | Phase 1 | A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food | June 2015 | September 2015 |
| NCT01739309 | Completed | Phase 2 | Study of LY2835219 for Mantle Cell Lymphoma | March 20, 2013 | September 5, 2022 |
| NCT05153135 | Completed | Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors | May 8, 2020 | July 31, 2020 | |
| NCT04256941 | Completed | Phase 2 | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study | May 31, 2019 | September 22, 2023 |
| NCT06179303 | Not yet recruiting | Phase 2 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | July 6, 2024 | June 1, 2026 |
| NCT06413706 | Not yet recruiting | Phase 2 | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | June 2024 | February 2028 |
| NCT05940493 | Not yet recruiting | Phase 2 | Abemaciclib in Newly Diagnosed Meningioma Patients | June 15, 2024 | December 2031 |
| NCT06366347 | Not yet recruiting | Phase 2 | ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | September 2024 | March 1, 2029 |
| NCT06025747 | Not yet recruiting | Phase 1 | Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma | July 1, 2024 | March 3, 2026 |
| NCT06380751 | Not yet recruiting | Phase 3 | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | April 18, 2024 | July 18, 2030 |
| NCT05774899 | Recruiting | Phase 1/Phase 2 | CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC | June 1, 2023 | June 1, 2026 |
| NCT02523014 | Recruiting | Phase 2 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | August 2015 | October 2024 |
| NCT02693535 | Recruiting | Phase 2 | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | March 14, 2016 | December 31, 2025 |
| NCT02925234 | Recruiting | Phase 2 | The Drug Rediscovery Protocol (DRUP Trial) | August 2016 | December 2027 |
| NCT03310879 | Recruiting | Phase 2 | Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | November 21, 2017 | April 30, 2025 |
| NCT03424005 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | April 2, 2018 | May 3, 2026 |
| NCT03675893 | Recruiting | Phase 2 | RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer | December 24, 2018 | August 1, 2029 |
| NCT03837821 | Recruiting | Early Phase 1 | (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer | February 5, 2019 | December 2025 |
| NCT03891784 | Recruiting | Phase 2 | Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | October 31, 2019 | September 30, 2026 |
| NCT03979508 | Recruiting | Phase 2 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | January 10, 2020 | July 31, 2024 |
| NCT03994796 | Recruiting | Phase 2 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | August 15, 2019 | June 2025 |
| NCT04040205 | Recruiting | Phase 2 | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | October 7, 2019 | June 1, 2027 |
| NCT04092673 | Recruiting | Phase 1/Phase 2 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | October 25, 2019 | March 31, 2025 |
| NCT04158362 | Recruiting | Phase 3 | Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer | June 11, 2020 | June 2028 |
| NCT04169074 | Recruiting | Phase 2 | Immune Modulation by Abemaciclib in HNSCC. (AIM Trial) | June 16, 2021 | June 30, 2024 |
| NCT04305834 | Recruiting | Phase 2 | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | March 25, 2020 | August 21, 2024 |
| NCT04391595 | Recruiting | Early Phase 1 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | July 8, 2020 | February 2025 |
| NCT04469764 | Recruiting | Phase 2 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | October 16, 2020 | July 1, 2026 |
| NCT04486352 | Recruiting | Phase 1/Phase 2 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | October 20, 2021 | October 2026 |
| NCT04523857 | Recruiting | Phase 2 | ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer | November 1, 2021 | December 2028 |
| NCT04584853 | Recruiting | Phase 3 | PreOperative Endocrine Therapy for Individualised Care With Abemaciclib | December 23, 2020 | March 31, 2032 |
| NCT04614194 | Recruiting | Phase 2 | Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | April 15, 2021 | April 15, 2028 |
| NCT04633239 | Recruiting | Phase 1 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | July 2, 2021 | December 1, 2024 |
| NCT04681768 | Recruiting | Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients | December 22, 2020 | December 2024 | |
| NCT05464173 | Recruiting | Phase 1/Phase 2 | Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib | July 1, 2022 | May 1, 2025 |
| NCT05501704 | Recruiting | Phase 2 | ETHAN - ET for Male BC | October 11, 2023 | April 1, 2036 |
| NCT05524584 | Recruiting | Phase 2 | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | August 31, 2022 | December 31, 2028 |
| NCT05548127 | Recruiting | Phase 1/Phase 2 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | February 23, 2023 | December 31, 2025 |
| NCT05563220 | Recruiting | Phase 1/Phase 2 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer | January 24, 2023 | August 31, 2026 |
| NCT05608252 | Recruiting | Phase 1/Phase 2 | VS-6766+Abema+Fulv in Met HR+/HER- BC | February 23, 2023 | December 31, 2028 |
| NCT05708235 | Recruiting | Phase 2 | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | April 1, 2024 | December 30, 2028 |
| NCT05714072 | Recruiting | Phase 1 | A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | January 25, 2023 | January 2025 |
| NCT05766410 | Recruiting | Phase 2 | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC | September 16, 2022 | September 30, 2026 |
| NCT05867251 | Recruiting | Phase 1/Phase 2 | Study of AVZO-021 in Patients With Advanced Solid Tumors | August 30, 2023 | January 31, 2030 |
| NCT05872204 | Recruiting | Phase 2 | Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer | November 30, 2023 | October 2026 |
| NCT05891093 | Recruiting | Phase 3 | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | June 1, 2023 | May 31, 2031 |
| NCT05933395 | Recruiting | Phase 2 | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor | October 10, 2023 | October 2031 |
| NCT05952557 | Recruiting | Phase 3 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | October 5, 2023 | May 6, 2037 |
| NCT05999994 | Recruiting | Phase 2 | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | January 22, 2020 | May 1, 2026 |
| NCT06001762 | Recruiting | Phase 2 | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | October 5, 2023 | January 1, 2027 |
| NCT06065748 | Recruiting | Phase 3 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | December 11, 2023 | December 30, 2028 |
| NCT06139107 | Recruiting | Phase 1 | RADIANT: Pre-op Radiation With Abemaciclib and Letrozole | June 21, 2024 | September 30, 2032 |
| NCT06169371 | Recruiting | Phase 4 | Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) | December 28, 2023 | November 2030 |
| NCT06188520 | Recruiting | Phase 1/Phase 2 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | December 5, 2023 | June 18, 2025 |
| NCT06365788 | Recruiting | Phase 2 | Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer | April 8, 2024 | December 2027 |
| NCT06409390 | Recruiting | Early Phase 1 | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | April 26, 2024 | April 2027 |
| NCT04750928 | Recruiting | Phase 1/Phase 2 | Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | November 29, 2021 | December 1, 2026 |
| NCT04791384 | Recruiting | Phase 1/Phase 2 | Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer | April 21, 2022 | January 2025 |
| NCT04802759 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | June 20, 2021 | October 31, 2026 |
| NCT04862663 | Recruiting | Phase 3 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | May 10, 2021 | August 14, 2029 |
| NCT04923542 | Recruiting | Phase 1/Phase 2 | Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases | November 30, 2021 | December 31, 2024 |
| NCT04941274 | Recruiting | Phase 1/Phase 2 | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | September 29, 2021 | June 1, 2028 |
| NCT04961996 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | August 27, 2021 | November 21, 2033 |
| NCT04964934 | Recruiting | Phase 3 | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | June 30, 2021 | November 26, 2027 |
| NCT04967521 | Recruiting | Phase 3 | SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma | November 11, 2021 | November 2024 |
| NCT04975308 | Recruiting | Phase 3 | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer | October 4, 2021 | August 31, 2027 |
| NCT05095207 | Recruiting | Phase 1/Phase 2 | Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | September 20, 2021 | October 2026 |
| NCT05113537 | Recruiting | Phase 1/Phase 2 | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | July 8, 2022 | July 31, 2027 |
| NCT05159245 | Recruiting | Phase 2 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | December 10, 2021 | November 25, 2026 |
| NCT05307705 | Recruiting | Phase 1 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | May 11, 2022 | May 2025 |
| NCT05372640 | Recruiting | Phase 1 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | August 10, 2023 | June 1, 2025 |
| NCT05386108 | Recruiting | Phase 1/Phase 2 | Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | August 31, 2022 | December 2025 |
| NCT05440786 | Recruiting | Phase 2 | CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma | September 20, 2022 | September 10, 2028 |
| NCT03655444 | Terminated | Phase 1/Phase 2 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | May 29, 2019 | August 24, 2020 |
| NCT03781960 | Terminated | Phase 2 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | July 31, 2019 | April 29, 2022 |
| NCT04801966 | Terminated | N/A | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | September 23, 2021 | December 30, 2022 |
| NCT04534283 | Terminated | Phase 2 | A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | October 5, 2020 | August 7, 2023 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT04003896 | Terminated | Phase 2 | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | September 24, 2021 | August 15, 2023 |
| NCT03997448 | Terminated | Phase 2 | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | August 26, 2019 | January 30, 2020 |
| NCT04305236 | Terminated | Phase 2 | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer | July 23, 2020 | February 16, 2022 |
| NCT04165031 | Terminated | Phase 1/Phase 2 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | November 28, 2019 | October 30, 2020 |
| NCT03130439 | Terminated | Phase 2 | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | May 26, 2017 | January 30, 2022 |
| NCT04031885 | Terminated | Phase 4 | A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer | August 14, 2019 | August 11, 2020 |
| NCT03356587 | Unknown status | Phase 2 | A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy | October 16, 2017 | December 31, 2020 |
| NCT04852081 | Unknown status | Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | January 1, 2021 | December 1, 2021 | |
| NCT04921904 | Unknown status | Phase 1/Phase 2 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | June 2021 | June 2024 |
| NCT04049227 | Unknown status | Early Phase 1 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | August 12, 2019 | July 1, 2023 |
| NCT04316169 | Withdrawn | Phase 1 | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | October 21, 2021 | January 2028 |
| NCT04351230 | Withdrawn | Phase 2 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer | November 11, 2020 | February 16, 2022 |
| NCT04118036 | Withdrawn | Phase 2 | Abemaciclib + Pembrolizumab In Glioblastoma | December 1, 2021 | December 1, 2024 |
| NCT03988114 | Withdrawn | Phase 4 | A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer | September 16, 2019 | March 23, 2023 |
| NCT04585724 | Withdrawn | Phase 1 | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases | June 12, 2020 | September 13, 2021 |
| NCT03846583 | Withdrawn | Phase 1 | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | June 28, 2020 | September 22, 2020 |
| NCT04220892 | Withdrawn | Early Phase 1 | Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | July 8, 2020 | July 8, 2020 |